Intercept Pharmaceuticals, Inc. (ICPT)
Stock Price:
$47.09 USD
0.57 (1.23%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.55B |
| Revenue (ttm) |
272.40M |
| Net Income (ttm) |
-347.39M |
| Shares Out |
32.94M |
| EPS (ttm) |
-10.74 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$47.09 |
| Previous Close |
$46.52 |
| Change ($) |
0.57 |
| Change (%) |
1.23% |
| Day's Open |
47.21 |
| Day's Range |
45.08 - 47.24 |
| Day's Volume |
1,126,683 |
| 52-Week Range |
44.50 - 125.00 |
More Stats
| Market Cap |
1.55B |
| Enterprise Value |
1.54B |
| Earnings Date (est) |
Jul 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.94M |
| Float |
26.63M |
| EPS (basic) |
-10.74 |
| EPS (diluted) |
-10.74 |
| FCF / Share |
-7.76 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.80M |
| Short Ratio |
7.12 |
| Short % of Float |
27.88% |
| Beta |
1.81 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
5.69 |
| PB Ratio |
44.19 |
| Revenue |
272.40M |
| Operating Income |
-311.93M |
| Net Income |
-347.39M |
| Free Cash Flow |
-252.75M |
| Net Cash |
15.08M |
| Net Cash / Share |
0.46 |
| Gross Margin |
90.96% |
| Operating Margin |
-114.51% |
| Profit Margin |
-127.50% |
| FCF Margin |
-92.79% |
| ROA |
-35.43% |
| ROE |
-295.33% |
| ROIC |
-27.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (24)
| Buy |
7 |
| Overweight |
0 |
| Hold |
17 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$70.77*
(50.29% upside)
Low
46.0
Current: 47.09
High
180.0
Target: 70.77
*Average 12-month price target from 22 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 252 | 180 | 131 | 24.95 | 2.78 | 1.74 | 1.62 | 2.45 | 1.81 | - |
| Revenue Growth | 40.15% | 37.3% | 424.85% | 796.87% | 59.7% | 7.4% | -33.69% | 35.51% | - | - |
| Gross Profit | 248 | 177 | 130 | 24.95 | 2.78 | 1.74 | 1.62 | 2.45 | 1.81 | - |
| Operating Income | -312 | -285 | -336 | -403 | -229 | -113 | -39.45 | -18.91 | -13.83 | -16.35 |
| Net Income | -345 | -309 | -360 | -413 | -226 | -283 | -67.79 | -43.64 | -12.74 | -15.09 |
| Shares Outstanding | 31.65 | 28.46 | 25.05 | 24.66 | 23.69 | 20.78 | 18.03 | 6.28 | 3.33 | 3.33 |
| Earnings Per Share | -10.89 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -7.36 | -4.73 | -5.40 |
| Operating Cash Flow | -237 | -241 | -265 | -342 | -163 | -87.74 | -28.01 | -15.75 | 2.61 | -13.66 |
| Capital Expenditures | -1.14 | -0.17 | -10.39 | -5.08 | -5.94 | -4.64 | -1.63 | -0.04 | -0.06 | -0.03 |
| Free Cash Flow | -238 | -241 | -276 | -348 | -169 | -92.38 | -29.64 | -15.79 | 2.54 | -13.69 |
| Cash & Equivalents | 657 | 436 | 415 | 689 | 628 | 240 | 145 | 110 | 17.71 | 15.50 |
| Total Debt | 532 | 371 | 356 | 341 | - | - | - | - | 0.08 | 0.33 |
| Net Cash / Debt | 125 | 64.91 | 59.24 | 348 | 628 | 240 | 145 | 110 | 17.63 | 15.16 |
| Assets | 755 | 509 | 484 | 739 | 656 | 254 | 150 | 112 | 19.47 | 17.12 |
| Liabilities | 703 | 490 | 468 | 424 | 53.61 | 23.26 | 67.91 | 46.27 | 22.03 | 8.80 |
| Book Value | 51.56 | 19.13 | 16.39 | 315 | 602 | 231 | 82.41 | 65.91 | -2.56 | 8.32 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Intercept Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
583 |
| CEO |
Mark E. Pruzanski |
Stock Information
| Ticker Symbol |
ICPT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ICPT |
| IPO Date |
October 11, 2012 |
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.